ID
45494
Description
Principal Investigator: Levi Garraway, M.D. Ph.D, Dana Farber Cancer Institute, Boston, MA USA; Broad Institute, Cambridge, MA USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000447 Prostate cancer is a prevalent cause of cancer morbidity and mortality in men. In order to characterize the full range of somatic mutations in protein-coding genes that may drive the growth of prostate cancer, we sequenced the exonic regions of genomic and tumor DNA from over 100 patients with high-risk primary prostate cancer. Using hybrid capture and paired end DNA sequencing, we identified mutations in several novel putative prostate cancer genes. We interrogated copy number changes across tumor genomes using high-density SNP arrays, and identified a molecular subtype of cancer characterized by mutation of the ubiquitin ligase subunit SPOP and copy number loss at specific genomic loci.
Link
Keywords
Versions (2)
- 10/24/22 10/24/22 - Simon Heim
- 12/13/22 12/13/22 - Kristina Keller
Copyright Holder
Levi Garraway, M.D. Ph.D, Dana Farber Cancer Institute, Boston, MA USA; Broad Institute, Cambridge, MA USA
Uploaded on
December 13, 2022
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000447 Prostate Cancer Genome Sequencing Project
Subject ID, age at onset, gender, primary diagnosis, cancer stage, PSA level, and radiation therapy of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, subject source ID, and consent groups of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Subject ID, age at onset, gender, primary diagnosis, cancer stage, PSA level, and radiation therapy of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Sample ID, analyte type [somatic or genomic DNA, total RNA], sample type [tumor or normal], type of material, body site where sample was collected, anatomical zone of the prostate from which sample derived, tumor grade, RNA integrity number of RNA sample, Gleason Score, fusion status of TMPRSS2-ERG gene of participant tumor, and percent of tumor specimen with grade 4 or 5 histology of samples obtained from participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
Similar models
Subject ID, age at onset, gender, primary diagnosis, cancer stage, PSA level, and radiation therapy of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, subject source ID, and consent groups of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Subject ID, age at onset, gender, primary diagnosis, cancer stage, PSA level, and radiation therapy of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Sample ID, analyte type [somatic or genomic DNA, total RNA], sample type [tumor or normal], type of material, body site where sample was collected, anatomical zone of the prostate from which sample derived, tumor grade, RNA integrity number of RNA sample, Gleason Score, fusion status of TMPRSS2-ERG gene of participant tumor, and percent of tumor specimen with grade 4 or 5 histology of samples obtained from participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
C2348585 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,2])
C3854607 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,2])
C4761063 (UMLS CUI [1,3])
C1522449 (UMLS CUI [1,2])